We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Neurocognitive Study for the Aging-a Longitudinal Study With a Greek Cypriot Cohort (NEUROAGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01481246
Recruitment Status : Recruiting
First Posted : November 29, 2011
Last Update Posted : April 29, 2022
Information provided by (Responsible Party):
Fofi Constantinidou, University of Cyprus

Brief Summary:
The Neurocognitive Study for the Aging (NEUROAGE) was initially funded by the Cyprus Innovation Foundation and has received subsequent funding by the European Union Regional Development Fund. The project focuses on the understanding of the effects of age on neurocognitive abilities such as attention, memory, language, categorization, and executive functioning. In addition, specific arms of the project investigate the effects of a theory-driven hierarchical training program, the Categorization Program, to improve cognitive abilities in adults with Mild Cognitive Impairment (MCI) and of a group intervention program focusing on cognitive and psychosocial abilities. Over 1000 adults ages 40 and older have been recruited in the NEUROAGE project thus far. The grant was awarded to the University of Cyprus, with Professor Fofi Constantinidou as the PI.

Condition or disease Intervention/treatment
Aging Memory Impairment Cognitive Decline Mild Cognitive Disorder Behavioral: Categorization training Behavioral: Psychosocial and Psychoeducational Group training

Detailed Description:

Given the fact that older adults are expected to live longer while maintaining their social and professional activities, the development of effective cognitive retraining methodologies designed to maximize independence has been of interest. In addition to changes caused by the normal aging process, older adults over 65 are at a high risk for developing dementia. About 8-12% of the older adult population will demonstrate a pre-dementia syndrome referred to as Mild Cognitive Impairment (MCI) which is considered a prodrome to dementia. Consequently, it is important to identify variables that contribute to the development of MCI as well as neurocognitive therapy approaches to help patients improve their level of functioning.

Categorization is one of the most fundamental cognitive processes. The ability to divide the world into discrete categories is a rudimentary process beginning early in life and continues to be developed and refined across the lifespan. This underlying process is crucial to a variety of neurocognitive abilities including attention and memory and can influence vocational and educational reintegration. Normal aging results in categorization deficits which in turn can interfere with the individual's ability to attend, remember, and organize information. This difficulty could hamper activities of daily living, social participation, and independence. This project implements an innovative treatment program based on current theoretical models of human cognition designed to improve neurocognitive abilities.

One of the objectives of the project is to provide evidence on the effectiveness of a systematic and hierarchical neurocognitive therapy method, the Categorization Program (CP) in adults with MCI and in normal older adults. It is hypothesized that the CP will be an effective treatment approach to improve categorization abilities in both groups of subjects. In addition, since 2020, we have been implementing a group intervention program as part of our recent funding to investigate its feasibility in healthy older adults and in adults with MCI.

The following activities have been taking place:

  1. Initially, a population-based sample of 500 older adults was tested using a battery of neuropsychological measures. Normal older adults are reassessed every two years. Currently, more than 800 healthy adults have been recruited in this project.
  2. Second, normal OA and adults with MCI have been randomly assigned into either the treated or untreated groups. The treated groups receive the CP training in order to test its effectiveness.
  3. Third, the long term effects of cognitive retraining is being assessed.
  4. Finally, the project examines the relationship between the categorization tasks, neuropsychological performance, functional outcome measures, and subject characteristics including health indices, education, and biomarkers. Theoretical constructs such as Cognitive Reserve have been explored as part of this project.

The long-term objective of this research program is to determine variables that influence cognitive decline in older adults and develop effective neurocognitive therapy techniques.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Neurocognitive Study for the Aging
Study Start Date : July 2009
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Normal Aging/Cognitive Decline
Health adults as well as adults with MCI and early stage AD are being recruited in the study
Behavioral: Categorization training
Behavioral intervention consisting of cognitive training exercises to improve categorization performance

Behavioral: Psychosocial and Psychoeducational Group training
Group treatment with a focus on psychosocial and psychoeducational intervention in healthy adults and in adults with cognitive decline. Ten week cycle, 2 hours per week group intervention study.

Primary Outcome Measures :
  1. Neuropsychological Tests [ Time Frame: on going ]
    a variety of cognitive tests as well as psychosocial measures are used in this project

Biospecimen Retention:   Samples With DNA
APOE phenotyping

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Normal older adults and adults with cognitive decline are recruited in this study

Inclusion Criteria:

  • healthy with no prior neurological history

Exclusion Criteria:

  • prior neurological history or significant psychiatric history

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01481246

Layout table for location contacts
Contact: Fofi Constantinidou, Ph.D. 35722892078 fofic@ucy.ac.cy

Layout table for location information
University of Cyprus Recruiting
Nicosia, Cyprus, 1678
Contact: Fofi Constantinidou, Ph.D.    35722894437    fofic@ucy.ac.cy   
Principal Investigator: Fofi Constantinidou, Ph.D.         
Sponsors and Collaborators
University of Cyprus
Layout table for investigator information
Principal Investigator: Fofi Constantinidou, Ph.D. University of Cyprus
Additional Information:
Layout table for additonal information
Responsible Party: Fofi Constantinidou, Professor, University of Cyprus
ClinicalTrials.gov Identifier: NCT01481246    
Other Study ID Numbers: Humanities/Society/0308(ΒΕ)/07
Humanities/Society/0308(ΒΕ)/07 ( Other Grant/Funding Number: Cyprus Research Promotion Foundation )
SKEPSH ( Other Grant/Funding Number: European Regional Development Fund )
EXCELLENCE/1216/0404 ( Other Grant/Funding Number: Cyprus Research Innovation Foundation )
First Posted: November 29, 2011    Key Record Dates
Last Update Posted: April 29, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Fofi Constantinidou, University of Cyprus:
cognitive decline
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders